Literature DB >> 12641911

The de novo selection of drug-resistant malaria parasites.

N J White1, W Pongtavornpinyo.   

Abstract

Antimalarial drug resistance emerges de novo predominantly in areas of low malaria transmission. Because of the logarithmic distribution of parasite numbers in human malaria infections, inadequately treated high biomass infections are a major source of de novo antimalarial resistance, whereas use of antimalarial prophylaxis provides a low resistance selection risk. Slowly eliminated antimalarials encourage resistance largely by providing a selective filter for resistant parasites acquired from others, and not by selecting resistance de novo. The de novo emergence of resistance can be prevented by use of antimalarial combinations. Artemisinin derivative combinations are particularly effective. Ensuring adequate treatment of the relatively few heavily infected patients would slow the emergence of resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641911      PMCID: PMC1691263          DOI: 10.1098/rspb.2002.2241

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  43 in total

1.  Antimalarial drug resistance and mortality in falciparum malaria.

Authors:  N White
Journal:  Trop Med Int Health       Date:  1999-07       Impact factor: 2.622

2.  Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.

Authors:  M B Reed; K J Saliba; S R Caruana; K Kirk; A F Cowman
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

3.  More on 'the efficacy of antifolate antimalarial combinations in Africa'.

Authors:  W M Watkins; E K Mberu; P A Winstanley; C V Plowe
Journal:  Parasitol Today       Date:  1999-04

4.  Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection.

Authors:  G M JEFFERY; D E EYLES
Journal:  Am J Trop Med Hyg       Date:  1955-09       Impact factor: 2.345

5.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

Review 6.  The prevention of antimalarial drug resistance.

Authors:  W Peters
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

7.  A simple model of the build-up of resistance to mixtures of anti-malarial drugs.

Authors:  C F Curtis; L N Otoo
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

Review 8.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria.

Authors:  I M Hastings; U D'Alessandro
Journal:  Parasitol Today       Date:  2000-08

9.  Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum.

Authors:  S Paget-McNicol; A Saul
Journal:  Parasitology       Date:  2001-05       Impact factor: 3.234

10.  Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria.

Authors:  N P Day; T D Pham; T L Phan; X S Dinh; P L Pham; V C Ly; T H Tran; T H Nguyen; D B Bethell; H P Nguyan; T H Tran; N J White
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

View more
  70 in total

Review 1.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

2.  Superinfection and the evolution of resistance to antimalarial drugs.

Authors:  Eili Y Klein; David L Smith; Ramanan Laxminarayan; Simon Levin
Journal:  Proc Biol Sci       Date:  2012-07-11       Impact factor: 5.349

Review 3.  Global phenotypic screening for antimalarials.

Authors:  W Armand Guiguemde; Anang A Shelat; Jose F Garcia-Bustos; Thierry T Diagana; Francisco-Javier Gamo; R Kiplin Guy
Journal:  Chem Biol       Date:  2012-01-27

Review 4.  Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum.

Authors:  Connor O'Brien; Philipp P Henrich; Neha Passi; David A Fidock
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

5.  Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.

Authors:  K Stepniewska; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

Review 6.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

7.  Benefits of using multiple first-line therapies against malaria.

Authors:  Maciej F Boni; David L Smith; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

8.  The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection.

Authors:  S Huijben; D G Sim; W A Nelson; A F Read
Journal:  J Evol Biol       Date:  2011-08-23       Impact factor: 2.411

Review 9.  Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.

Authors:  Ambrose O Talisuna; Corine Karema; Bernhards Ogutu; Elizabeth Juma; John Logedi; Andrew Nyandigisi; Modest Mulenga; Wilfred F Mbacham; Cally Roper; Philippe J Guerin; Umberto D'Alessandro; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2012-11       Impact factor: 25.071

Review 10.  Antimalarial drug resistance.

Authors:  Nicholas J White
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.